blinatumomab
amgen,astellas
['blinatumomab']
congress|#ash22 |poster
matthew greenwood, presented preliminary results on the use of blinatumomab in protocol i phase 2 of bfm-based protocol for ayas with ph-neg all(all09 study); higher rates of day 79 mrd negativity was observed when compared to all06 cohort 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm